Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Wynn Resorts, Limited — how do they compare? Vertex Pharmaceuticals Incorporated trades at $508.92 (market cap $127.55B), while Wynn Resorts, Limited trades at $75.77 (market cap $7.75B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 16.5× Wynn Resorts, Limited's market cap, and Wynn Resorts, Limited pays a 1.33% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Wynn Resorts, Limited for 76 Days on average.
| VRTX | WYNN | |
|---|---|---|
Market Cap | $127.55B | $7.75B |
Volume | 1,487,944 | 2,243,813 |
Sector | Health | Consumer Cyclical |
52-Week High | $557.96 | $133.09 |
52-Week Low | $407.37 | $74.97 |
Typical Hold Time | 120 Days | 76 Days |
Enterprise Value | $121.68B | $17.99B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Wynn Resorts (WYNN) trades at $74.97, down 2.15% today, with a bearish technical signal despite bullish oscillators. The company reported mixed Q2 2026 results, beating EPS estimates but facing margin pressures. Revenue reached $7.14B in 2025, though net income declined to $327M. Analysts maintain a strong buy consensus with a $132.36 price target, while institutional activity shows mixed positioning amid high debt levels and significant capital expenditure plans.
The outlook for WYNN hinges on Macau recovery and successful execution of UAE expansion, but rising capex and debt servicing costs pose risks. Current valuation metrics appear reasonable with P/E of 18.06 and EV/EBITDA of 9.23, though investors should monitor margin trends and project timelines closely given the stock's significant discount to analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
